London, UK 11th January 2007 – Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, today announce that a milestone has been reached following entry of Stimuvax® into a global phase 3 trial in patients with unresectable stage 3 Non Small Cell Lung Cancer (NSCLC).
